Teva (yes, like the sandals) makes winter boots now. We tested them in a polar vortex.
Teva’s first pair of true winter boots deliver on their promises. They’re not meant for arctic adventures but are great at ...
FiercePharma2d
Teva's multiple sclerosis stalwart Copaxone gets FDA boxed warning for anaphylaxis risk
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
Teva's Win in Ception Dispute Affirmed by Delaware Supreme Court
The Delaware Supreme Court affirmed Friday a trial court’s decision in favor of Teva Pharmaceutical Industries Ltd.'s US unit ...
Teva Pharmaceuticals: Promising Growth Prospects and Buy Rating Reaffirmed
Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on TEVA stock, giving a Buy rating on January 21.Invest ...
Teva Hits Biden With New Challenge to Medicare Drug Price Talks
Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days ...
BioSpace2d
FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
UBS lifts Teva stock price target to $30, maintains Buy rating
UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...
Teva price target raised to $30 from $28 at UBS
UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for ...
Teva Challenges Drug Price Law's Impact On Innovation, Generics
Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, ...
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar ...
news.stocktradersdaily2d
(TEVA) Technical Pivots with Risk Controls
Technical analysis for Teva Pharmaceutical Industries Limited American Depositary Shares TEVA including support levels resistance levels and stop losses for TEVA ...
Drug Store News4d
Teva partners with Klinge Biospharma, Formycon for Eylea biosimilar candidate in Europe, Israel
Teva Pharmaceuticals International GmbH, a subsidiary of Teva, has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, ...